EcoDrugPlus

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSOKIG00005019712
Gene Symbol: PARP1
3 Cross references
207 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 2

Ensembl ID : ENSOKIG00005041360
Gene Symbol: PARP2
3 Cross references
185 Possible Orthologues:

Poly(Adp-Ribose) Polymerase Family Member 3

Ensembl ID : ENSOKIG00005014706
Gene Symbol: PARP3
3 Cross references
194 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSOKIG00005009370
Gene Symbol: PORCN
1 Cross references
186 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSOKIG00005017665
Gene Symbol: PORCN
1 Cross references
191 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSOKIG00005039906
Gene Symbol: PORCN
1 Cross references
187 Possible Orthologues:

Porcupine O-Acyltransferase Like

Ensembl ID : ENSOKIG00005036787
Gene Symbol: PORCNL
1 Cross references
191 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSOKIG00005005490
Gene Symbol: KCNMA1
1 Cross references
229 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSOKIG00005013746
Gene Symbol: KCNMA1
1 Cross references
234 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSOKIG00005012984
Gene Symbol: KCNMA1
1 Cross references
235 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSOKIG00005026716
Gene Symbol: KCNMA1
3 Cross references
226 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily N Member 4

Ensembl ID : ENSOKIG00005001299
Gene Symbol: KCNN4
3 Cross references
179 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).